Duration of mitosis in RPE-1 cells exposed to various drugs that perturb spindle formation (37°C)a
| Drug/concentration . | MTs . | Duration of mitosis ± SD (N)b . | Approximate hours in mitosisc . | Survival . |
|---|---|---|---|---|
| %d | ||||
| Control | + | 18 ± 3 (33) | 0.3 | 100 |
| 3.2 μM nocodazole | − | 1,140 ± 732 (25) | 19 | 71 |
| 250 nM colcemid | − | 1,303 ± 362 (24) | 22 | 60 |
| 25 nM vinblastine | − | 1,784 ± 602 (24)e | 30 | 26 |
| 1 μM vinblastine | − | 1,820 ± 530 (37) | 30 | 21 |
| 1 μM maytansine | − | 1,558 ± 407 (50) | 26 | 50 |
| 500 nM taxol | + | 744 ± 399 (117) | 12 | 81 |
| 5.0 μM S-Trityl-l-cysteinef | + | 1,179 ± 310 (160) | 20 | 84 |
| 2.5 μM dimethylenastrong | + | 1,218 ± 424 (241) | 20 | 80 |
| 50 nM nocodazole | + | 153 ± 58 (200) | 3 | 100 |
| 5 nM vinblastine | + | 234 ± 140 (180) | 4 | 95 |
| 5 nM taxol | + | 161 ± 85 (171) | 3 | 99 |
| Drug/concentration . | MTs . | Duration of mitosis ± SD (N)b . | Approximate hours in mitosisc . | Survival . |
|---|---|---|---|---|
| %d | ||||
| Control | + | 18 ± 3 (33) | 0.3 | 100 |
| 3.2 μM nocodazole | − | 1,140 ± 732 (25) | 19 | 71 |
| 250 nM colcemid | − | 1,303 ± 362 (24) | 22 | 60 |
| 25 nM vinblastine | − | 1,784 ± 602 (24)e | 30 | 26 |
| 1 μM vinblastine | − | 1,820 ± 530 (37) | 30 | 21 |
| 1 μM maytansine | − | 1,558 ± 407 (50) | 26 | 50 |
| 500 nM taxol | + | 744 ± 399 (117) | 12 | 81 |
| 5.0 μM S-Trityl-l-cysteinef | + | 1,179 ± 310 (160) | 20 | 84 |
| 2.5 μM dimethylenastrong | + | 1,218 ± 424 (241) | 20 | 80 |
| 50 nM nocodazole | + | 153 ± 58 (200) | 3 | 100 |
| 5 nM vinblastine | + | 234 ± 140 (180) | 4 | 95 |
| 5 nM taxol | + | 161 ± 85 (171) | 3 | 99 |
Minutes from first frame after NEB to first frame including the initial signs of cytokinesis and/or telophase membrane blebbing (in cells that exited mitosis).
N = total numbers of cells (pooled from ≥2 separate long-term recordings obtained on different days).
Mean duration of mitosis in hours.
Percentage of cells that exited mitosis (versus dying in mitosis).
These data are from a single experiment.
An Eg5 inhibitor (and nonnatural derivative of the α–amino acid cysteine).
An Eg5 inhibitor (a new monastrol analogue).